✦ LIBER ✦

Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

✍ Scribed by Tanja Fehm; Peter Maimonis; Stephen Weitz; Yosh Teramoto; Alexander Katalinic; Wolfram Jäger

Book ID: 110228407
Publisher: Springer US
Year: 1997
Tongue: English
Weight: 37 KB
Volume: 43
Category: Article
ISSN: 0167-6806
DOI: 10.1023/a:1005700812422

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic effect of amenorrhoea and ele

Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients

✍ P Poikonen; T Saarto; I Elomaa; H Joensuu; C Blomqvist 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Influence of histology on the effectiven

Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer

✍ Wilfred Truin; Adri C. Voogd; Gerard Vreugdenhil; Maurice J.C. van der Sangen; M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 246 KB

The influence of classical prognostic fa

The influence of classical prognostic factors and adjuvant chemotherapy on disease outcome in early grade 3 node-negative, and 1–3 node-positive breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF), or untreated patients

✍ S Susnjar; I Kezic; Z Neskovic-Konstantinovic; D Gavrilovic; D Nikolic-Vukosavlj 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 319 KB

Overexpression of c-erbB-2 is related to

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment

✍ B. Linderholm; J. Andersson; B. Lindh; L. Beckman; M. Erlanson; K. Edin; B. Tave 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 249 KB

P69 Long term impact on disease-free sur

P69 Long term impact on disease-free survival (DFS) andoverall survival (OS) of adjuvant anthracycline (AA) based chemotherapy (CT) in node positive (N+) breast cancer patients (PTS): A report of 258 pts with 20 years (Y) of follow-up (FU)

✍ H. Auvray; J. Ferriere; C. Molucon; J. Dauplat; J. Achard; F. Kwiatkowski; P. Ch 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views